Abstract
Early detection of prostate cancer (PC) using prostate-specific antigen (PSA) in blood reduces PC-death among unscreened men. However, due to modest specificity of PSA at commonly used cut-offs, there are urgent needs for additional biomarkers contributing enhanced risk classification among men with modestly elevated PSA.
Original language | English |
---|---|
Pages (from-to) | 951-962 |
Journal | Proteomics Clinical Applications |
Volume | 8 |
Issue number | 11-12 |
DOIs | |
Publication status | Published - 2014 |
Subject classification (UKÄ)
- Cell and Molecular Biology